initial public offerings (IPOs) trading on American exchanges

Thursday, April 28, 2022

Zymeworks (ZYME) : 5-year performance

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
  • Sector(s): Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 455
  • incorporated in 2003 
  • HQ: Vancouver, Canada.

First day of trading Friday April 28, 2017
Vancouver, British Columbia-based biotherapeutics provider Zymeworks Inc has raised $58.5 million for its IPO after pricing its 4.5 million shares at $13 per share. The stock began trading April 28, 2017 on the New York Stock Exchange and on the Toronto Stock Exchange under the ticker symbol “ZYME";
Citigroup Global Markets Canada Inc., Barclays Capital Inc. and Wells Fargo Securities, LLC are the lead underwriters. Zymeworks'  pre-IPO backers include BDC Capital, Lumira Capital, CTI Life Sciences Fund, Fonds de solidarit√© FTQ, Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital and Merlin Nexus.

No comments:

Post a Comment